La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Co-Diagnostics Crescita futura

Future criteri di controllo 0/6

Si prevede che i ricavi e gli utili di Co-Diagnostics diminuiranno rispettivamente del 97.1% e 8.9% all'anno, mentre si prevede che l'EPS crescerà del 7.6% all'anno.

Informazioni chiave

-8.9%

Tasso di crescita degli utili

7.6%

Tasso di crescita dell'EPS

Medical Equipment crescita degli utili	17.9%
Tasso di crescita dei ricavi	-97.1%
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Low
Ultimo aggiornamento	12 Aug 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Here's Why We're Watching Co-Diagnostics' (NASDAQ:CODX) Cash Burn Situation

Jun 14

One Co-Diagnostics, Inc. (NASDAQ:CODX) Analyst Just Slashed Their Estimates By A Consequential 14%

May 18

A Look At The Intrinsic Value Of Co-Diagnostics, Inc. (NASDAQ:CODX)

Apr 14

Co-Diagnostics: Hold Thesis Remains Well Intact

Sep 07

Co-Diagnostics stock sinks ~37% after hours on Q2 results miss, hurt by lower volumes

Aug 11

Co-Diagnostics, Inc. (NASDAQ:CODX) Shares Could Be 29% Below Their Intrinsic Value Estimate

Mar 28

Co-Diagnostics: Swinging For The Fences

Jan 24

Does Co-Diagnostics (NASDAQ:CODX) Deserve A Spot On Your Watchlist?

Dec 28

Why Co-Diagnostics Is A Solid Covid-19 Play

Aug 19

Co-Diagnostics, Inc.'s (NASDAQ:CODX) Share Price Boosted 42% But Its Business Prospects Need A Lift Too

Aug 14

Co-Diagnostics gets CE marking for direct saliva SARS-CoV-2 test

Jun 18

Co-Diagnostics: No One-Hit Wonder

Jun 04

Previsioni di crescita degli utili e dei ricavi

NasdaqCM:CODX - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2025	2	-43	N/A	N/A	1
12/31/2024	4	-38	N/A	N/A	1
6/30/2024	9	-38	-25	-24	N/A
3/31/2024	7	-39	-26	-25	N/A
12/31/2023	7	-35	-23	-22	N/A
9/30/2023	5	-43	-23	-22	N/A
6/30/2023	7	-38	-16	-14	N/A
3/31/2023	12	-32	-8	-7	N/A
12/31/2022	34	-14	5	7	N/A
9/30/2022	53	15	14	15	N/A
6/30/2022	78	28	25	26	N/A
3/31/2022	101	40	36	37	N/A
12/31/2021	98	37	40	41	N/A
9/30/2021	105	42	55	56	N/A
6/30/2021	96	46	52	53	N/A
3/31/2021	93	51	41	42	N/A
12/31/2020	75	42	27	28	N/A
9/30/2020	48	28	6	7	N/A
6/30/2020	26	10	-3	-3	N/A
3/31/2020	2	-6	-6	-5	N/A
12/31/2019	0	-6	-6	-6	N/A
9/30/2019	0	-6	-5	-5	N/A
6/30/2019	0	-6	-5	-5	N/A
3/31/2019	0	-6	-5	-4	N/A
12/31/2018	0	-6	-4	-4	N/A
9/30/2018	0	-6	-4	-4	N/A
6/30/2018	0	-8	-5	-4	N/A
3/31/2018	0	-8	N/A	-4	N/A
12/31/2017	0	-7	N/A	-3	N/A
9/30/2017	0	-6	N/A	-3	N/A
6/30/2017	0	-3	N/A	-2	N/A
3/31/2017	N/A	-2	N/A	-1	N/A
12/31/2016	N/A	-2	N/A	-1	N/A
9/30/2016	0	-2	N/A	-1	N/A
12/31/2015	0	-2	N/A	-2	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che CODX rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che CODX rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che CODX rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che i ricavi di CODX diminuiranno nei prossimi 3 anni ( -97.1% all'anno).

Ricavi ad alta crescita: Si prevede che i ricavi di CODX diminuiranno nei prossimi 3 anni ( -97.1% all'anno).

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di CODX è previsto essere elevato tra 3 anni

Co-Diagnostics Crescita futura

Future criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Consensus revenue estimates increase by 143%

Consensus revenue estimates increase by 474%

Price target increased by 50% to US$3.00

Consensus revenue estimates fall by 43%

Consensus revenue estimates fall by 83%

Consensus revenue estimates fall by 14%

Recent updates

Consensus revenue estimates increase by 143%

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Co-Diagnostics, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Co-Diagnostics, Inc., Annual General Meeting, Aug 29, 2024

Co-Diagnostics, Inc. Submits First FDA 510(k) Application for Co-Dx PCR Pro Platform

Here's Why We're Watching Co-Diagnostics' (NASDAQ:CODX) Cash Burn Situation

New minor risk - Share price stability

First quarter 2024 earnings: EPS and revenues miss analyst expectations

New minor risk - Shareholder dilution

Co-Diagnostics, Inc. to Report Q1, 2024 Results on May 09, 2024

Co-Diagnostics, Inc. Appoints Executive Appointments

Full year 2023 earnings released

New major risk - Revenue and earnings growth

Co-Diagnostics, Inc. to Report Q4, 2023 Results on Mar 14, 2024

Co-Diagnostics, Inc. Completes Submission to FDA for Co-Dx PCR Pro

Chairman exercised options and sold US$58k worth of stock

Consensus revenue estimates increase by 474%

Price target increased by 50% to US$3.00

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Co-Diagnostics, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Co-Diagnostics, Inc. Appoints Ivory Chang as Chief Regulatory Affairs Officer

Consensus revenue estimates fall by 43%

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Co-Diagnostics, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Co-Diagnostics, Inc., Annual General Meeting, Aug 30, 2023

Co-Diagnostics, Inc. Receives Funding for Co-Dx PCR Home Platform from NIH RADx Tech Program

One Co-Diagnostics, Inc. (NASDAQ:CODX) Analyst Just Slashed Their Estimates By A Consequential 14%

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Co-Diagnostics, Inc. to Report Q1, 2023 Results on May 11, 2023

A Look At The Intrinsic Value Of Co-Diagnostics, Inc. (NASDAQ:CODX)

Consensus revenue estimates fall by 83%

Full year 2022 earnings: EPS and revenues miss analyst expectations

Investor sentiment improves as stock rises 16%

Chairman exercised options and sold US$111k worth of stock

Consensus revenue estimates fall by 14%

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

High number of new and inexperienced directors

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Co-Diagnostics, Inc. Appoints Dr. Mark Poritz as New Chief Scientific Officer

Co-Diagnostics, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Investor sentiment improved over the past week

Pomerantz Law Firm Announces the Filing of a Class Action Against Co-Diagnostics, Inc. and Certain Officers

Co-Diagnostics: Hold Thesis Remains Well Intact

Investor sentiment deteriorated over the past week

Kaplan Fox & Kilsheimer LLP Files Class Action Suit in the United States District Court for the Southern District of New York Against Co-Diagnostics, Inc

Price target decreased to US$15.33

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Co-Diagnostics stock sinks ~37% after hours on Q2 results miss, hurt by lower volumes

Co-Diagnostics, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Co-Diagnostics, Inc., Annual General Meeting, Aug 31, 2022

Co-Diagnostics spikes on shipments of monkeypox test

Estimating The Intrinsic Value Of Co-Diagnostics, Inc. (NASDAQ:CODX)

Investor sentiment improved over the past week

Now 20% undervalued after recent price drop

Co-Diagnostics: Well Priced, Long-Term Value Remains Too Distant

Now 24% undervalued after recent price drop

Co-Diagnostics, Inc. Completes Principal Design of Test for Monkeypox Virus

Chairman exercised options and sold US$59k worth of stock

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Investor sentiment deteriorated over the past week

Price target decreased to US$19.33

High number of new and inexperienced directors

Investor sentiment deteriorated over the past week

Co-Diagnostics: Where's Eikon?

High number of new and inexperienced directors

Consensus EPS estimates increase by 36%

Co-Diagnostics, Inc. (NASDAQ:CODX) Shares Could Be 29% Below Their Intrinsic Value Estimate

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week